Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
rucaparib 200 MG Oral Tablet [Rubraca]
Known as:
Rubraca (as rucaparib camisylate) 200 MG Oral Tablet
, Rubraca 200 MG Oral Tablet
, rucaparib camsylate 200 mg ORAL TABLET, FILM COATED [Rubraca]
National Institutes of Health
Create Alert
Related topics
Related topics
13 relations
Brilliant blue FCF
Indigo Carmine
Magnesium stearate
Oral Tablet
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Rucaparip (Rubraca®) induces necrosis via upregulating the expression of RIP1 and RIP3 in ovarian cancer cells.
Yonghe Wang
,
Yunxia Zheng
,
Yuchen Hao
Die Pharmazie
2020
Corpus ID: 219704381
In the current study we investigated the inhibitory effect of rucaparib (Rubraca®) on human ovarian cancer SKOV3 and A2780 cells…
Expand
Review
2019
Review
2019
Rucaparib: A Review in Ovarian Cancer
Matt Shirley
Targeted Oncology
2019
Corpus ID: 71147857
Rucaparib (Rubraca®) is a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor with potent activity against PARP-1, -2 and…
Expand
Review
2017
Review
2017
Rucaparib: First Global Approval
Yahiya Y. Syed
Drugs
2017
Corpus ID: 35935870
Rucaparib (Rubraca™) is an oral, small molecule, poly (ADP-ribose) polymerase inhibitor being developed by Clovis Oncology, Inc…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE